KOICA donates Celltrion's Herzuma to Ukraine

The Ukrainian government specifically requested a supply of the cancer-fighting drug Herzuma

Herzuma, Celltrion's breast and gastric cancers treatment
Herzuma, Celltrion's breast and gastric cancers treatment
Jung-Eun Kim 1
2022-12-26 17:42:39 likesmile@hankyung.com
Bio & Pharma

Celltrion Healthcare Co. said on Monday that Herzuma (ingredient name: Trastuzumab) was dispatched to patients in Ukraine by the Korea International Cooperation Agency (KOICA).

The latest donation was led by KOICA at the Ukrainian government's request. KOICA purchased 5 billion won ($3.9 million) worth of Herzuma from Celltrion Healthcare and donated it to Ukraine.

It is understood that the Ukrainian government selected Herzuma after considering the efficacy and safety of treatment, and the trust it has gained with European doctors, given that the supply of treatments for breast and stomach cancers was disrupted by the war.

Trastuzumab is one of the best-known anti-cancer drugs and has been widely used in Europe for years to treat HER2-positive breast cancer and gastric cancer.

"As we are currently running the Remsima SC donation program in Turkey and Pakistan, we will continue to fulfill our social responsibility to promote global medical welfare," said a Celltrion Healthcare official.

Write to Jung-Eun Kim at likesmile@hankyung.com
#Celltrion Healthcare #Herzuma #Trastuzumab #KOICA #Ukraine #korea celltrion herzuma ukraine #ukraine government koica herzuma

Celltrion applies for FDA approval for Remsima SC

Celltrion applies for FDA approval for Remsima SC

Celltrion's Remsima Celltrion Ltd. said on Friday it had applied the previous day for permission from the US Food and Drug Administration (FDA) for Remsima SC, an autoimmune disease treatment.Remsima SC (infliximab) is a self-injectable drug developed as a subcutaneous injection formulation.A C

Celltrion to seek FDA approval for sale of Remsima SC by year-end

Celltrion to seek FDA approval for sale of Remsima SC by year-end

Remsima SC by Celltrion (Courtesy of Celltrion) Celltrion Inc. said it has confirmed the effectiveness and safety of Remsima SC in its third-phase global clinical trials, conducted on 438 patients of ulcerative colitis and 343 Crohn's disease patients.The South Korean pharmaceutical company cla

Celltrion wins trial against Regeneron for US patent lawsuit over biosimilar

Celltrion wins trial against Regeneron for US patent lawsuit over biosimilar

An exterior of the Celltrion plant complex in Seoul South Korean biopharmaceutical company Celltrion Inc. announced Friday that it won its first trial against New York-based biotech giant Regeneron Pharmaceuticals, Inc. regarding two patents. This lawsuit is related to the US patents for t

Celltrion's Q3 earnings boosted by Remsima sales in Europe

Celltrion's Q3 earnings boosted by Remsima sales in Europe

(Courtesy of Celltrion) South Korean biopharmaceutical giant Celltrion Inc. announced 654.6 billion won ($478.2 million) in revenue and 213.8 billion won in operating profit on a consolidated basis during the third quarter, the company said in a preliminary report on Nov. 9.If realized, the fig
(* comment hide *}